New FDA Indication for First Line Tarceva in EGFR Mutation-Positive NSCLC May Be Good for Roche but BAD for Patients: Here's Why

Article

Earlier this week, the FDA approved the oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tarceva (erlotinib) for the approximately 10% of advanced NSCLC patients with an activating EGFR mutation in North America and Europe (approximately 30% in Asia).

Subscribe to Genentech